Xeris Biopharma Holdings Inc. Common Stock (XERS)
Stock · NASDAQ · Health Care
$10.33as of 10/16/2026
Price chart
Active signals
XERS Signal Track Record
How signals performed across all stocks →What XERS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -2.0% | 49% | September 18, 2026 |
| Bollinger Band Breakout | 28 | +2.1% | 57% | September 28, 2026 |
| Bollinger Band Breakdown | 19 | +7.7% | 63% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +11.7% | 71% | February 19, 2026 |
| Any 20-session window (baseline) | +3.6% | 59% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XERS
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary p…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 435
- Website
- www.xerispharma.com/
Fundamentals
- 1-day range
- $9.85$10.07
- Market cap
- $1.27B
- P/E (trailing)
- —
- P/E (forward)
- 26.88
- EPS (trailing)
- $-0.11
- Dividend yield
- —
- Beta
- 0.87
- Avg. volume
- 2.22M
How Xeris Biopharma Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Xeris Biopharma Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XERSXeris Biopharma Holdings Inc. Common Stock$10.31▲ 2.38%Market cap $1.27BP/E —$5.25$11.33
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- AKTSAktis Oncology Inc. Common stock$15.06▼ 5.93%Market cap $1.30BP/E —$14.72$34.19
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
- MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$9.55▼ 6.92%Market cap $1.33BP/E —$8.8$23.29
- SDGRSchrodinger Inc. Common Stock$22.6▼ 11.30%Market cap $1.33BP/E —$10.95$33.78
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings Inc. Common Stock | $1.27B | — | $10.31 | ▲ 2.38% | $5.25$11.33 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| AKTS Aktis Oncology Inc. Common stock | $1.30B | — | $15.06 | ▼ 5.93% | $14.72$34.19 |
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
| MLTX MoonLake Immunotherapeutics Class A Ordinary Shares | $1.33B | — | $9.55 | ▼ 6.92% | $8.8$23.29 |
| SDGR Schrodinger Inc. Common Stock | $1.33B | — | $22.6 | ▼ 11.30% | $10.95$33.78 |
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Pieper Steven · August 12, 2026 · Sale5.0K @ $8.5
- McCulloch Kevin · August 3, 2026 · Sale15.0K @ $8.02
- Hecht Beth · August 3, 2026 · Sale16.7K @ $8.01
- Pieper Steven · July 7, 2026 · Sale27.6K @ $8.52
- Pieper Steven · July 6, 2026 · Sale17.4K @ $8.5
- McCulloch Kevin · July 1, 2026 · Sale90.0K @ $8.03
- Nerissa Kreher · July 1, 2026 · Grant37.9K @ $8
- Nerissa Kreher · July 1, 2026 · Grant33.6K
- Hecht Beth · July 1, 2026 · Sale16.7K @ $8.03
- Brady James Aloysius · June 4, 2026 · Grant33.0K @ $6.15
- Brady James Aloysius · June 4, 2026 · Grant24.2K
- HALKUFF DAWN · June 4, 2026 · Grant33.0K @ $6.15
- HALKUFF DAWN · June 4, 2026 · Grant24.2K
- HALKUFF DAWN · June 4, 2026 · Sale20.0K @ $6.09
- BORMANN-KENNEDY BARBARA-JEAN ANNE · June 4, 2026 · Grant33.0K @ $6.15
Institutional Ownership
March 31, 2026
- Total shares held
- 98.74M
- Total value held
- $562.18M
- Institutional holders
- 232
- Unknown12.95M
- Unknown7.79M
- Unknown4.66M
- Unknown4.29M
- Unknown4.11M
- Unknown3.23M
- Unknown2.92M
- Unknown2.67M
- Unknown2.57M
- Unknown2.27M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit
Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.
Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit. Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.